Campbell & CO Investment Adviser LLC Takes $484,000 Position in Legend Biotech Co. (NASDAQ:LEGN)

Campbell & CO Investment Adviser LLC acquired a new position in shares of Legend Biotech Co. (NASDAQ:LEGNFree Report) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 7,201 shares of the company’s stock, valued at approximately $484,000.

Other institutional investors have also recently bought and sold shares of the company. BluePath Capital Management LLC acquired a new stake in Legend Biotech during the 3rd quarter worth about $32,000. American International Group Inc. acquired a new stake in Legend Biotech during the 2nd quarter worth about $33,000. Lazard Asset Management LLC acquired a new stake in Legend Biotech during the 4th quarter worth about $33,000. Coppell Advisory Solutions LLC acquired a new stake in Legend Biotech during the 2nd quarter worth about $41,000. Finally, Atlas Capital Advisors LLC acquired a new stake in Legend Biotech during the 2nd quarter worth about $57,000. 49.61% of the stock is currently owned by institutional investors and hedge funds.

Legend Biotech Stock Down 0.8 %

Shares of LEGN stock opened at $60.48 on Tuesday. The stock’s 50 day simple moving average is $59.16 and its 200 day simple moving average is $63.94. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.61 and a quick ratio of 8.51. Legend Biotech Co. has a twelve month low of $42.90 and a twelve month high of $77.32.

Legend Biotech (NASDAQ:LEGNGet Free Report) last issued its quarterly earnings data on Monday, November 20th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.14. Legend Biotech had a negative return on equity of 40.03% and a negative net margin of 207.24%. The business had revenue of $96.00 million for the quarter, compared to the consensus estimate of $97.25 million. The firm’s revenue was up 250.4% compared to the same quarter last year. As a group, equities research analysts forecast that Legend Biotech Co. will post -2.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group assumed coverage on Legend Biotech in a research note on Monday, November 6th. They set a “buy” rating and a $90.09 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $87.00 price target on shares of Legend Biotech in a research note on Friday, December 22nd. Barclays raised their price target on Legend Biotech from $93.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 24th. Finally, Scotiabank assumed coverage on Legend Biotech in a research note on Tuesday, December 19th. They set a “sector perform” rating and a $65.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $82.41.

Get Our Latest Stock Report on LEGN

About Legend Biotech

(Free Report)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).

Further Reading

Want to see what other hedge funds are holding LEGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Legend Biotech Co. (NASDAQ:LEGNFree Report).

Institutional Ownership by Quarter for Legend Biotech (NASDAQ:LEGN)

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.